These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 26994216)

  • 1. Methods for meta-analysis of pharmacodynamic dose-response data with application to multi-arm studies of alogliptin.
    Langford O; Aronson JK; van Valkenhoef G; Stevens RJ
    Stat Methods Med Res; 2018 Feb; 27(2):564-578. PubMed ID: 26994216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study.
    Del Prato S; Camisasca R; Wilson C; Fleck P
    Diabetes Obes Metab; 2014 Dec; 16(12):1239-46. PubMed ID: 25132212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes.
    Covington P; Christopher R; Davenport M; Fleck P; Mekki QA; Wann ER; Karim A
    Clin Ther; 2008 Mar; 30(3):499-512. PubMed ID: 18405788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies.
    Pratley RE; McCall T; Fleck PR; Wilson CA; Mekki Q
    J Am Geriatr Soc; 2009 Nov; 57(11):2011-9. PubMed ID: 19793357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study.
    Nauck MA; Ellis GC; Fleck PR; Wilson CA; Mekki Q;
    Int J Clin Pract; 2009 Jan; 63(1):46-55. PubMed ID: 19125992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glycemic control after addition of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes showing inadequate response to thrice-a-day treatment with α-glucosidase inhibitors.
    Masuda K; Aoki K; Kamiko K; Takihata M; Ito Y; Nagakura M; Kawasaki S; Akema N; Hasegawa M; Nakajima S; Shinoda K; Toumura S; Tsunoda S; Enomoto H; Shimotomai H; Terauchi Y
    Expert Opin Pharmacother; 2013 Jun; 14(9):1111-8. PubMed ID: 23600363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alogliptin: safety, efficacy, and clinical implications.
    Marino AB; Cole SW
    J Pharm Pract; 2015 Feb; 28(1):99-106. PubMed ID: 24532820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension.
    Seino Y; Fujita T; Hiroi S; Hirayama M; Kaku K
    Curr Med Res Opin; 2011 Nov; 27 Suppl 3():21-9. PubMed ID: 22106975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study.
    Inagaki N; Onouchi H; Maezawa H; Kuroda S; Kaku K
    Lancet Diabetes Endocrinol; 2015 Mar; 3(3):191-7. PubMed ID: 25609193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of pharmacometric approaches to evaluate effect of weight and renal function on pharmacokinetics of alogliptin.
    Naik H; Czerniak R; Vakilynejad M
    Br J Clin Pharmacol; 2016 Apr; 81(4):700-12. PubMed ID: 26617339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results.
    Gibbs JP; Fredrickson J; Barbee T; Correa I; Smith B; Lin SL; Gibbs MA
    J Clin Pharmacol; 2012 Oct; 52(10):1494-505. PubMed ID: 22162539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study.
    Seino Y; Fujita T; Hiroi S; Hirayama M; Kaku K
    Curr Med Res Opin; 2011 Sep; 27(9):1781-92. PubMed ID: 21806314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study.
    Kaku K; Itayasu T; Hiroi S; Hirayama M; Seino Y
    Diabetes Obes Metab; 2011 Nov; 13(11):1028-35. PubMed ID: 21682833
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study.
    Seino Y; Miyata Y; Hiroi S; Hirayama M; Kaku K
    Diabetes Obes Metab; 2012 Oct; 14(10):927-36. PubMed ID: 22583697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alogliptin and Gliclazide Similarly Increase Circulating Endothelial Progenitor Cells in Type 2 Diabetes Patients.
    Negro R; Greco EL; Greco G
    Exp Clin Endocrinol Diabetes; 2019 Apr; 127(4):215-219. PubMed ID: 29558784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
    Pratley RE; Reusch JE; Fleck PR; Wilson CA; Mekki Q;
    Curr Med Res Opin; 2009 Oct; 25(10):2361-71. PubMed ID: 19650752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacological and clinical profile of alogliptin benzoate (NESINA®)].
    Takeuchi K; Fujita T; Hiroi S
    Nihon Yakurigaku Zasshi; 2011 Jan; 137(1):43-50. PubMed ID: 21233588
    [No Abstract]   [Full Text] [Related]  

  • 18. Alogliptin in Patients with Type 2 Diabetes Receiving Metformin and Sulfonylurea Therapies in the EXAMINE Trial.
    White WB; Heller SR; Cannon CP; Howitt H; Khunti K; Bergenstal RM;
    Am J Med; 2018 Jul; 131(7):813-819.e5. PubMed ID: 29581078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of alogliptin and glipizide for composite endpoint of glycated haemoglobin reduction, no hypoglycaemia and no weight gain in type 2 diabetes mellitus.
    Del Prato S; Fleck P; Wilson C; Chaudhari P
    Diabetes Obes Metab; 2016 Jun; 18(6):623-7. PubMed ID: 26865535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naïve patients with type 2 diabetes: a randomized, double-blind, 6-month study.
    Pratley RE; Fleck P; Wilson C
    Diabetes Obes Metab; 2014 Jul; 16(7):613-21. PubMed ID: 24400655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.